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(57) ABSTRACT 
A method is described to construct genetically modified 
strains of steroid degrading micro-organisms wherein the 
method comprises inactivation of at least one gene involved in 
methylhexahydroindanedione propionate degradation. 
Strains with (multiple) inactivated Steroid degrading enzyme 
genes according to the invention can be used in the accumu 
lation of steroid intermediates. Accumulation products are for 
example 3aC.-H-4C.(3'-propionic acid)-7af3-methylhexahy 
dro-1,5-indanedione (HIP), 3-hydroxy-9,10-secoandrosta-1, 
3.5(10)-triene-9,17-dione (3-HSA), 1,4-androstadiene-3,17 
dione (ADD) and 3ao-H-4C.(3'-propionic acid)-5C.-hydroxy 
7af3-methylhexahydro-1-indanone-6-lactone (HIL). 
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METHOD FOR THE PRODUCTION OF 
MODIFIED STEROID DEGRADING 
MICROORGANISMS AND THEIR USE 
0001. This application is a non-provisional application 
that claims priority under 35 U.S.C. S 119(e) of provisional 
application U.S. Ser. No. 60/957,030 filed Aug. 21, 2007, the 
contents of which are hereby incorporated by reference in its 
entirety. 
0002 The invention relates to a method to prepare geneti 
cally modified micro-organisms having inhibited capacity for 
nucleus degradation of steroids, to the use of Such micro 
organism in Steroid accumulation as well as to said modified 
micro-organisms. 
0003. The ability to degrade steroids is widespread in acti 
nobacteria and requires a set of enzymes degrading the side 
chain and the steroid nucleus structure. Rhodococcus species 
are well-known in the art for their large catabolic potential. 
Several Rhodococcus species are able to degrade natural phy 
tosterols, which are inexpensive starting materials for the 
production of bioactive steroids. For instance, it is known that 
Rhodococcus Strains treated with mutagens and/or incubated 
with enzyme inhibitors convert sterols into 4-androstene-3, 
17-dione and 1,4-androstadiene-3,17-dione. 
It is further known, that methylhexahydroindanedione propi 
onate (HIP; 3ao-H-4C.(3'-propionic acid)-7a3-methyl 
hexahydro-1,5-indanedione) and 5-hydroxy-methylhexahy 
droindanone propionate (HIL; 3ao-H-4C (3'-propionic acid)- 
5C-hydroxy-7af3-methylhexahydro-1-indanone-8-lactone) 
are formed during the microbial degradation of steroids and 
sterols by actinobacteria (FIG. 1), e.g. by Rhodococcus equi, 
Nocardia restricta, Nocardia corallina, Streptomyces rubes 
cens and Mycobacterium fortuitum. Reportedly, HIL forma 
tion has also been observed during deoxycholic acid degra 
dation by Pseudomonas sp. 
HIP and HIL are valuable staring compounds for the synthe 
sis of medically important steroids, such as 19-norsteroids. 
0004 Previous studies have shown that in the steroid cata 
bolic pathway, degradation of intermediate HIP presumably 
occurs via a 3-oxidation mechanism. The first step in H P 
degradation in Rhodococcus equi is assumed to be an ATP 
dependent CoA activation of HIP, followed by a reduction of 
the 5'-keto moiety of HIP-CoA by a HIP-reductase, resulting 
in the formation of HIL-CoA (FIG. 1). Further it is known 
from literature that in HIP degradation CoA activation is a 
prerequisite prior to reduction. Microbial CoA-transferases 
are usually comprised of two pairs of C. and B subunits, 
forming an OB enzyme complex, encoded by two separate 
genes. The crystal structure of glutaconate CoA transferase of 
Acidaminococcus fermentans has been solved and reported in 
literature, and further a glutamate residue in the B subunit of 
glutaconate CoA transferase of A. fermentans and propionate 
CoA transferase of Clostridium propionicum has been iden 
tified as catalytic residue. 
Recently, two gene clusters involved in testosterone degrada 
tion have been identified in Comamonas testosteroni TA441, 
one of which contains ORFs suggested to be involved in HIP 
degradation (Horinouchi, M. et al. Microbiology 147: 3367 
3375 (2001), and Biochem Biophy's Res Comm324:597–604 
(2004)). The specific genes for HIP degradation, however, are 
not known. 
0005. The present invention relates to the identification of 
three genes in Rhodococcus erythropolis SQ1 involved in 
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methylhexahydroindanedione propionate degradation (ipd); 
two of these genes encode a HIP CoA transferase (ipdA and 
ipdB), and one gene encodes a putative HIL-(3'O-hydrox 
ypropionyl)-CoA dehydrogenase (ipdF). According to one 
aspect of the present invention the nucleotide sequences of 
the ipdA gene, ipdB gene and ipdF gene of R. erythropolis 
SQ1 have been provided as a gene cluster (SEQ ID NO:1). 
The present invention also includes DNA sequences compris 
ing nucleotides 1814-2722 of SEQ ID NO: 1 (ipdA), nucle 
otides 2719-3474 of SEQ ID NO:1 (ipdB), and nucleotides 
927-13 of SEQ ID NO:1 (ipdF). Furthermore, the present 
invention includes an IpdA protein comprising the amino acid 
sequence SEQ ID NO:3 or orthologues therefrom, an IpdB 
protein comprising the amino acid sequence SEQID NO:5 or 
orthologues therefrom, and an IpdF protein comprising the 
amino acid sequence SEQID NO:7 or orthologues therefrom. 
Preferably these orhologues belong to the genus Rhodococ 
cus but also related genera belonging to the family of Acti 
nomycetes, such as Nocardia, Corynebacterium, Mycobac 
terium, and Arthrobacter, can be used. More particularly, the 
ipdA protein is encoded by nucleotides 1814-2722 of SEQID 
NO:1. TheipdB protein is encoded by nucleotides 2719-3474 
of SEQID NO:1. The ipdF protein is encoded by nucleotides 
927-13 of SEQID NO:1. 
0006 Finally, the invention includes DNA sequences 
encoding the above-mentioned IpdA protein, IpdB protein, 
and an IpdF protein. 
0007 Primarily, the present invention relates to a method 
to construct a genetically modified strain of a steroid-degrad 
ing micro-organism, wherein the method comprises inactiva 
tion of at least one gene involved in methylhexahydroin 
danedione propionate degradation. In particular, the method 
comprises inactivation of multiple genes D involved in meth 
ylhexahydroindanedione propionate degradation. Another 
embodiment of the invention relates to a method wherein at 
least one gene encoding a HIP CoA transferase is inactivated, 
and particularly wherein the HIP CoA transferase genes 
ipdA, encoding the C-subunit of HIP CoA transferase, and 
ipdB, encoding the B-subunit of HIP CoA transferase, are 
inactivated. 
A further embodiment relates to a method to construct a 
genetically modified Strain of a steroid-degrading micro-or 
ganism wherein a gene encoding a HIL-(3'O-hydroxypropio 
nyl)-CoA dehydrogenase (ipdF) is inactivated. 
0008 Still another embodiment is a genetically modified 
micro-organism wherein at least one gene involved in meth 
ylhexahydroindanedione propionate degradation has been 
inactivated according to the present invention. Preferred are 
micro-organisms belonging to the family of Actinomycetes. 
More preferred are micro-organisms belonging to the genus 
Rhodococcus. Most preferred embodiments are the strains 
Rhodococcus erythropolis RG37 and Rhodococcus erythro 
polis RG33. 
The micro-organism strains Rhodococcus erythropolis RG37 
and Rhodococcus erythropolis RG33 have been deposited at 
the Deutsche Sammlung von Mikroorganismen und Zellkul 
turen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 
Braunschweig, Germany under the accession numbers DSM 
18157 and DSM 18156 respectively. These deposits have 
been made under the terms of the Budapest Treaty. 
0009. According to another aspect of the present invention 
micro-organisms possessing gene inactivation according to 
the present invention can be used in the preparation of inter 
mediates of the steroid catabolic pathway by accumulation 
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thereof. When 9C.-hydroxy-4-androstene-3,17-dione 
(9CHAD) is incubated with a mutant strain in which HIP 
CoA transferase is inhibited (e.g. by inactivation of the ipdAB 
genes) accumulation of HIP occurs, a starting material for the 
synthesis of 19-norsteroids. Also, in this conversion 3-hy 
droxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 
(3-HSA) is formed as accumulation product. Therefore, 
another embodiment of the present invention is the use of a 
genetically modified strain of a micro-organism wherein the 
ipdAB genes are inactivated according to the present inven 
tion, in the preparation of 3ao-H-4C.(3'-propionic acid)-7af3 
methylhexahydro-1,5-indanedione (HIP) and/or 3-hydroxy 
9,10-secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) by 
growing said strain on a culture medium comprising 9CHAD. 
Another embodiment of the invention relates to the use of a 
genetically modified strain of a micro-organism wherein the 
ipdAB genes are inactivated according to the invention, in the 
preparation of 1,4-androstadiene-3,17-dione (ADD) by 
growing said strain on a culture medium comprising 4-an 
drostene-3,17-dione (AD). 
0010. A further embodiment of the present invention is the 
use of a genetically modified Strain of a micro-organism 
wherein the ipdF gene is inactivated according to the present 
invention, in the preparation of HIL by growing said strain on 
a culture medium comprising AD. Another embodiment is the 
use of a genetically modified Strain of a micro-organism 
wherein the ipdF gene is inactivated according to the present 
invention, in the preparation of 3aC.-H-4C.(3'-propionic acid)- 
7a3-methylhexahydro-1,5-indanedione (HIP) and/or 3-hy 
droxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 
(3-HSA) by growing said strain on a culture medium com 
prising 9CHAD. 
0011 Inactivation of genes is a powerful tool for analysis 
of gene function and for introduction of metabolic blocks. 
Gene disruption with a non-replicative vector carrying a 
selective marker is the commonly used method for gene inac 
tivation. Construction of strains with desirable properties via 
metabolic pathway engineering approaches, however, may 
require the stepwise inactivation or replacement of several 
genes. This is only possible when a suitable strategy for 
introduction of unmarked gene deletions or gene replace 
ments, allowing infinite rounds of metabolic engineering 
without being dependent on multiple markers, is available. 
Methods for introduction of unmarked gene deletions in acti 
nobacteria, in particular in the genus Rhodococcus have been 
reported e.g. in WO 01/31050. 
0012. An advantage of unmarked mutation is that it allows 
the repetitive introduction of mutations in the same strain. 
Foreign DNA (vector DNA) is removed in the process of 
introducing the mutation. Newly introduced vector DNA, for 
the introduction of a second mutation, therefore cannot inte 
grate at the site of the previous mutation (by homologous 
recombination between vector DNA's). Integration will defi 
nitely happen if vector DNA is still present in the chromo 
Some and will give rise to a large number of false-positive 
integrants. The system enables the use of a sole antibiotic 
gene for the introduction of an infinite number of mutations. 
Unmarked mutation also allows easy use in the industry 
because of the absence of heterogeneous DNA allowing easy 
disposal of fermentation broth. 
Gene inactivation by gene deletion enables the construction 
of stable, non-reverting mutants. Especially small genes 
(<500 bp) are inactivated more easily by gene deletion com 
pared to gene disruption by a single recombination integra 
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tion. Gene deletion mutagenesis can also be applied to inac 
tivate a cluster of several genes from the genome. The gene 
deletion mutagenesis strategy can be applied also for gene 
replacement (e.g. changing wild type into mutant gene). 
0013 The preferred strainformutagenesis of the catabolic 
steroid ipd genes is Rhodococcus erythropolis. However, 
unmarked gene deletion of similar genes in other species, 
genetically accessible by e.g. conjugation or electrotransfor 
mation, is conceivable if the molecular organization is the 
same (or similar) as in R. erythropolis SQ1. Preferably these 
species belong to the genus Rhodococcus but also related 
genera belonging to the family of Actinomycetes, such as 
Nocardia, Mycobacterium, and Arthrobacter, can be used. 
0014. As a further embodiment of the present invention, 
for further gene inactivation, the same methods may be used 
again, or, alternatively, UV irradiation or chemical means 
Such as nitroguanidine or diepoxyethaan may be used. Meth 
ods to introduce gene mutations in that way are well known in 
the art. 
Also, methods to construct vehicles to be used in the 
mutagenesis protocol are well known (Sambrook et al., 
Molecular Cloning: a Laboratory Manual, Cold Spring Har 
bor Laboratory Press, Cold Spring Harbor, latest edition). 
Furthermore, techniques for site directed mutagenesis, liga 
tion of additional sequences, PCR, sequencing of DNA and 
construction of Suitable expression systems are all, by now, 
well known in the art. Portions or all of the DNA encoding the 
desired protein can be constructed synthetically using stan 
dard solid phase techniques, preferably to include restriction 
sites for ease of ligation. 
Modifications and variations of the method for introducing 
disrupted gene mutations or unmarked gene deletion as well 
as transformation and conjugation will be obvious to those 
skilled in the art from the foregoing detailed description of the 
invention. Such modifications and variations are intended to 
come within the scope of present application. 
LEGENDS TO THE FIGURES 
0015 FIG.1. Scheme showing the proposed sterol/steroid 
(AD and cholesterol) catabolic pathways of R. erythropolis 
SQ1 and degredation of the HIP propionate side chain by 
B-oxidation. The ipd genes putatively involved in HIP degra 
dation are indicated between brackets. The ipdAB genes, 
encoding the HIP-CoA transferase, and ipdF, encoding the 
HIL-(3'o-hydroxypropionyl)-CoA dehydrogenase, were 
deleted in parent strain SQ1, resulting in strain RG 37 and 
strain RG33 respectively. The kshAB genes encode the two 
component enzyme system 3-ketosteroid 9C.-hydroxylase 
(KSH). The kshB gene is involved in both cholesterol and AD 
degradation (Vander Geize R. et al.: Mol. Microbiol. 45:1007 
1018 (2002)). The kstD and kstD2 genes encode 3-ketoster 
oid A1-dehydrogenases (van der Geize et al.: Microbiology 
148: 3285-3292 (2002)). 
0016 FIG. 2. Schematic overview of an 11 kb genomic 
DNA fragment of R. erythropolis strain SQ1, containing the 
ipd gene cluster. Also shown are several pRESQ derived 
constructs (Table 1) used in functional complementation 
experiments of HIL growth deficient UV-mutant strains AP10 
and AP20. PCR primers used to construct gene deletion 
mutant RG37 are indicated as P1-P4. IpdF-F and IpdF-R are 
PCR primers used to check ipdF gene deletion in RG33. 
(0017 FIG. 3. Degradation of HIL (0.5 mgmL) in glu 
cose (20 mM) mineral medium by parent strain SQ1 (closed 
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circles), ipdAB mutant strain RG37 (triangles) and ipdF 
mutant strain RG33 (open circles). 
0018 FIG. 4. Gas chromatograms of samples taken 72h 
after addition of AD, 90HAD or HIP from cultures of (A) 
ipdAB mutant strain RG37. (B) ipdF mutant strain RG33 and 
(C) parent strain SQ1, following growth to late exponential 
phase in glucose (20 mM) mineral medium. Numbers above 
peeks indicate the following compounds: 1, HIP; 2 HIP; 3. 
AD; 4, 3-HSA: 5, ADD. Identities of compounds were veri 
fied using authentic samples. 
0019. A person skilled in the art will understand how to 
use the methods and materials described and referred to in this 
document in order to construct micro-organisms according to 
the present invention. 
The following examples are illustrative for the invention and 
should in no way be interpreted as limiting the scope of the 
invention. 
EXAMPLES 
0020 (A) Isolation of UV-induced Mutants of R. erythro 
polis SQ1 Blocked in HIL. Degradation 
HIL growth deficient mutants (HIL) of R. erythropolis SQ01 
growing well on mineral glucose agar plates, were selected 
following UV mutagenesis. Mutants with a glucose"/HIL 
growth phenotype were selected. Bioconversion experiments 
were subsequently performed to identify mutants that were 
blocked in the first step of HIL. degradation. It was found that 
mutant AP10 degraded HIL very slowly, while mutant AP20 
was completely blocked in HIL. degradation. Strains AP10 
and AP20 were selected for functional complementation with 
a genomic library of R. erythropolis to identify the genes 
encoding the first steps in HIL. degradation. 
(B) Molecular Characterization of the ipd Gene Cluster Fol 
lowing Functional Complementation of HIL Growth Nega 
tive Mutants AP10 and AP20 
0021 Agenomic library of R. erythropolis, constructed in 
the Rhodococcus-E. coli shuttle vector pRESQ (van der 
Geize R. et al.: Mol Microbiol. 45:1007-1018 (2002)), was 
introduced into mutant strains AP10 and AP20 to comple 
ment its mutant HIL growth phenotype. This resulted in the 
isolation of two plasmids, p.AR1 and pAR2000, that were able 
to restore growth of AP10 and AP20, respectively. Attempts 
for cross-complementation, introducing pAR1 into mutant 
AP20 and pAR2000 into mutant AP10, did not restore growth 
on HIL mineral agar plates, indicating that different genes 
had been inactivated in these two mutants (FIG. 2). Restric 
tion analysis of pAR1 and pAR2000 confirmed the unique 
ness of both plasmids, revealing different restriction patterns. 
Subsequent nucleotide sequence analysis revealed overlap of 
approximately 0.2 kb between both plasmids, resulting in a 
total contiguous sequence of about 11 kb (GC content, 
62.1%). The contiguous DNA sequence revealed a total num 
ber of 10 ORFs. Database similarity searches indicated that 
several genes were homologous to genes involved in B-OXi 
dation. 
The genes were tentatively designated ipdA to ipdH, because 
of their expected involvement in methylhexahydroindanedi 
one propionate degradation (Table 2, FIGS. 1 and 2). The 
ipdABH genes appear to be translationally coupled (ATGA 
start-stop codons), probably comprising an operon. This 
operon most likely includes the ipdE gene as well, since the 
start codon of ipdA is separated by only 7 nt from the stop 
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codon of ipdE. The putative ipdEABH operon structure is 
highly conserved among many actinomycetes and, to a lesser 
extent, in C. testosteroni TA441. 
(C) Molecular Characterization and Unmarked In-frame 
Gene Deletion Indicate that ipdAB Encode a CoA-transferase 
Involved in HIP and HIL. Degradation 
A series of sub-clones of pAR1 were constructed in pRESQ in 
order to determine which genes had been inactivated by the 
UV treatment in mutant AP10 (FIG. 2). A 2.8 kb DNA frag 
ment of the insert of pAR1 (FIG. 2), carrying ipdA and ipdB 
as intact genes, was cloned into pRESQ (pAR10, Table 1, 
FIG. 2) and introduced into AP10. This fragment could func 
tionally complement mutant AP10, indicating that either 
ipdA or ipdB had become inactivated in AP10. The ipdA and 
ipdB genes encode proteins of 302 amino acids (ipdA, Mw 
33.2 kDa) and 251 amino acids (IpdB, Mw 27.1 kDa), respec 
tively. Database similarity searches revealed that IpdA con 
tains the PfamO1144 signature of Coenzyme A transferases 
(http://www.sanger.ac.uk/Software/Pfam?) as well as the 
COG 1788 signature (http://www.ncbi.nlm.nih.gov/Struc 
ture/cdd/cdd.shtml) of Ato D, the C. subunit of acyl CoA: 
acetate/3-ketoacid CoA transferase of E. coli. IpdB further 
more contains the COG2057 signature of Ato A, the subunit 
of acyl CoA:acetate/3-ketoacid CoA transferase of E. coli. 
IpdA and IpdB also share amino acid sequence similarity 
with GctA (25% identity, Mw 35.7 kDa) and GctB (25% 
identity, Mw 29.2 kDa), the C. and B subunits of glutaconate 
CoA-transferase of A. fermentans, respectively (Mack M. et 
al.; Eur: J. Biochem. 226: 41-51 (1994)). Thus, IpdA and IpdB 
encode the C. and B subunit of a CoA-transferase involved in 
HIL. degradation. 
(D) Construction of Mutant RG37 
0022. An unmarked ipdAB gene deletion mutant of parent 
R. erythropolis strain SQ1 was constructed to confirm the 
involvement of ipdAB in HIL. degradation. This mutant, des 
ignated R. erythropolis Strain RG37, was constructed using 
mutagenic plasmid pAR31 via the sacB counter-selection 
method (van der Geize et al. FEMS Microbiol. Lett. 205:197 
202 (2001)). Simultaneous gene deletion of both ipdA and 
ipdB resulted in a single in-frame ORF remnant of 249 nt in 
the genome of RG37, encoding the first 46 amino acids of 
IpdA and the last 36 amino acids of IpdB. Gene deletion was 
confirmed by PCR using the P1 forward and P4 reverse prim 
ers (FIG. 2). Using these primers, PCR products of 1.56 kb 
and 2.96 kb were found with genomic DNA of mutant strain 
RG37 and parent strain SQ1, respectively. 
(E) Degradation of HIL using Mutant Strain RG37 as Com 
pared to Parent Strain SQ1 
Inactivation of the ipdAB genes rendered mutant strain RG37 
unable to grow on mineral agar medium Supplemented with 
HIL or HIP as sole carbon and energy source, confirming the 
involvement of ipdAB in HIL and HIP degradation. Incuba 
tion of HIL (0.5g'L') with parent strain SQ1 resulted in a 
substantial degradation of HIL over a period of five days 
(FIG.3). However, no degradation of HIL was observed after 
5 days in bioconversion experiments with mutant strain RG37 
(FIG. 3). The ipdAB genes thus encode the C. and B subunits, 
respectively, of a HIL CoA transferase, the first step in HIL 
degradation. 
(F) Inactivation of ipdAB Results in Impaired Hydroxylation 
of Steroid Catabolic Pathway Intermediates 
Since HIP and HIL are expected intermediates in steroid 
degradation (FIG. 1), we studied the ability of mutant strain 
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RG37 to grow on 4-androstene-3,17-dione (AD), 9C-hy 
droxy-4-androstene-3,17-dione (9CHAD) and cholesterol. 
Growth of strain RG37 in mineral medium supplemented 
with either AD, 9CHAD or cholesterol revealed that RG37 
was unable to grow on these steroid Substrates as sole carbon 
and energy sources. 
We subsequently studied the biotransformation of AD by 
cultures of RG37 grown to late exponential phase in glucose 
mineral medium. Strain RG37 was able to partly convert AD 
into ADD, resulting from 3-ketosteroid A 1-dehydrogenase 
(KSTD) activity (van der Geize et al.: Appl. Environ. Micro 
biol. 66: 2029-2036 (2000) and Microbiology 148: 3285 
3292 (2002), FIG. 1). However, AD and ADD were not 
degraded further and HIP or HIL formation was not observed 
(FIG.4A). These results showed that the ipdAB gene deletion 
had a suppressive effect on AD/ADD 9C.-hydroxylation. The 
mutant phenotype of strain RG37 is similar to the 3-ketoster 
oid 9C.-hydroxylase (KSH) negative mutant phenotypes of 
the kshA and kshB mutant strains R. erythropolis RG2 and 
strain RG4, respectively, we previously described (van der 
Geize R. et al.: Mol. Microbiol. 45:1007-1018 (2002)). The 
kshA and kshB genes encode the terminal oxygenase com 
ponent (Ksha) and oxygenase-reductase component (KshB) 
of KSH, respectively, involved in 9C.-hydroxylation of AD 
(forming 9CHAD) and 4-cholestene-3-one. The kshB gene 
deletion mutant strain RG4 is blocked in 9C.-hydroxylation of 
AD, ADD and 4-cholestene-3-one. Thus, inactivation of 
ipdAB apparently impairs KSH enzyme activity in R. eryth 
ropolis SQ1. Biotransformation of 9C.-hydroxylated AD 
(9CHAD) with mutant strain RG37 resulted in degradation of 
9CHAD and the accumulation of intermediates identified as 
3-hydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 
(3-HSA) and HIP (FIG. 4A). The accumulation of 3-HSA 
from 9CHAD was interesting and indicated that also 4-hy 
droxylation of 3-HSA, the proposed next step in 3-HSA deg 
radation (Horinouchi, M. et al.: Biochem Biophy's Res Comm 
324: 597-604 (2004), was impaired by the ipdAB deletion. 
Deletion of the ipdAB genes thus appears to have a marked 
inhibitory effect on steroid degradation, particularly on the 
hydroxylation of pathway intermediates, explaining why 
growth is not observed with strain RG37 using AD and 
9OHAD as sole carbon and energy sources. As stated earlier, 
strain RG37 is also unable to grow on cholesterol as sole 
carbon and energy source, which is likely due to Suppression 
of 9C.-hydroxylation of 4-cholestene-3-one blocking further 
degradation. 
Based on these results we conclude that the ipdAB genes 
encode the C. and B subunit of a CoA transferase with activity 
towards HIP and HIL. Since HIP is the expected actual sub 
strate of the ipdAB encoded enzyme in the steroid degrada 
tion to pathway (FIG. 1), the name HIP CoA-transferase is 
used. 
(G) Molecular Characterization and Unmarked Gene Dele 
tion of ipdF Suggests that IpdF is a HIL-(3'O-hydroxypropio 
nyl)-CoA Dehydrogenase 
A set of sub-clones of plasmid pAR2000 in pRESQ was 
introduced into UV mutant AP20 in order to identify the gene 
inactivated in this mutant (FIG. 2). A 1.9 kb DNA fragment of 
the insert of p AR2000 (pAR2010: Table 1, FIG. 2) was still 
able to functionally complement the AP20 phenotype. The 
ipdF gene was the sole intact gene on this DNA fragment. We 
thus concluded that ipdF had been inactivated in the AP20 
mutant. 
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0023 The ipdF gene encodes a protein (IpdF) of 304 
amino acids (31.1 kDa). Analysis of the amino acid sequence 
revealed the presence of a PfamO0106 signature of the short 
chain dehydrogenase/reductase (SDR) superfamily. More 
over, IpdF contains the glycine motif (GX(3)GXG (amino 
acids 14-20) and the Yx(3)K motif (amino acids 171-175) 
typical for classical SDR proteins (Kallberg et al.: Eur: J. 
Biochem 269: 4409-4017 (2002)). The highest similarities 
(71% identity, 82% similarity) were found with hypothetical 
proteins of the SDR superfamily from several actinomycetes, 
as well as with ORF27 (53% identity, 68% similarity) of C. 
testosterone TA 441 (Horinouchi, M. et al.; Microbiology 
147:3367-3375 (2001) and Biochem Biophy's Res Comm324; 
(0024) 597-604 (2004)). In all these bacteria, the genomic 
location of the corresponding gene was in close proximity to 
the location of their ipdAB gene orthologues. IpdF further 
more has extensive similarity (37% identity) with the N-ter 
minal (amino acids 1-323) part of mammalian 17 B-hydrox 
ysteroid dehydrogenase IV (HSD17B4; Leenders et al.; Eur: 
J. Biochem, 222: 221-227 (1994)), also known as peroxiso 
mal multifunctonal protein 2 (MFP-2: Dieuaide-Noubhani et 
al.; Biochem. J. 325; 367-73 (1997)). As the name implies, 
HSD17B4/MFP-2 is a multifunctional protein (737 amino 
acids, 80 kDa) exhibiting several enzymatic activities. The 
N-terminal portion of HSD17B4/MFP-2 is cleaved off as a 32 
kDa enzyme, having 17 B-hydroxysteroid dehydrogenase and 
3-hydroxyacyl-CoA dehydrogenase activities (Adamski et 
al.; Steroids 62: 159-163 (1997)). Based on these similarities 
it is assumed that IpdF is the HIL-(3'o-hydroxypropionyl)- 
CoA dehydrogenase involved in 3-oxidation of the propi 
onate side chain of HIL (FIG. 1). 
(H) Construction of Mutant RG33 
0025 AnipdF gene deletion mutant strain RG33 was con 
structed from R. erythropolis SQ1 to confirm the involvement 
of IpdF in HIP, HIL, and steroid degradation. An internal 
DNA fragment (0.43 kb) of wild type ipdF gene (915bp) was 
deleted (FIG. 2) using pAR2015 (Table 1; see “Experimental 
procedures' section) as mutagenic plasmid. Following ipdF 
gene deletion, a frame-shifted ORF remnant of 484 bp. 
encoding a nonsense protein of 98 amino acids, was intro 
duced, Genuine ipdF gene deletion was confirmed by PCR 
using ipdF forward (IpdF-F) and reverse (IpdF-R) primers 
(see “Experimental procedures' section). A PCR product of 
499 bp was found with genomic DNA isolated from mutant 
strain RG33, compared to a 930 bp PCR fragment for wild 
type ipdF with genomic DNA isolated from parent strain 
SQ1. 
(I) Degradation of HIL using Mutant Strain RG33 
0026. Mutant strain RG33 was unable to grow on mineral 
medium supplemented with HIL (0.5 gL) or HIP (0.5 
g"L') as sole carbon and energy source. Moreover, degrada 
tion of HIL (0.5 g L') was impaired and HIL concentrations 
decreased more slowly in biotransformation experiments 
with RG33 over a period of 5 days compared to wild type 
(FIG. 3). 
(J) Inactivation of ipdF Results in HIL. Accumulation from 
AD 
Strain RG33 was also not able to grow in mineral liquid 
medium supplemented with AD, 9CHAD or cholesterol as 
sole carbon and energy sources, Biotransformation of AD by 
liquid cultures of strain RG33 grown to late exponential phase 
in glucose mineral medium revealed that, in contrast to strain 
RG37,9C.-hydroxylation was not impaired and accumulation 
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of HIL from AD occurs (FIG. 4B). Incubation of RG33 cul 
tures with 90HAD on the other hand. resulted in the accu 
mulation of 3-HSA, HIP and HIL, indicating that degradation 
of 9CHAD was affected by ipdF inactivation. The accumu 
lation of the expected substrate of IpdF, HIL-(3'C.-hydrox 
ypropionyl)3OH-HIL, could not be verified with authentic 
3OH-HIL. Authentic 3OH-HIL could not be obtained from a 
commercially source nor synthesized easily. However, the 
high similarity of ipdF to 3-hydroxyacyl-CoA dehydrogenase 
domain of mammalian HSD17B4/MFP-2 multifunctional 
protein in addition to the fact that ipdF is essential for growth 
on HIP/HIL strongly implies that ipdF encodes HIL-(3'C.- 
hydroxypropionyl)-CoA dehydrogenase. 
Experimental Procedures 
(K) Bacterial Strains, Plasmids and Growth Conditions 
0027 Plasmids and bacterial strains used are listed in 
Table 1. Rhodococcus strains were cultivated at 30° C. and 
200 rpm. Complex medium (LBP) contained 1% (wt/vol) 
bacto-peptone (Difco, Detroit, Mich.), 0.5% (wt/vol) yeast 
extract (BBL Becton Dickinson and Company, Cockeysville, 
Md.) and 1% (wt/vol) NaCl. Mineral medium (MM) con 
sisted of 4.65 g L' KHPO, 1.5 g L' NaHPO HO, 3 g 
L' NHCl, 1 g L' MgSO4.7H2O, and Vishniac trace ele 
ments (pH 7). Filter sterilized glucose (20 mM) was added to 
autoclaved medium. Steroids, HIP, and HIL, supplied by Dio 
synth bv. (Oss, The Netherlands), were solubilized in DMSO 
(50 mgmL) and added to autoclaved medium to final con 
centration of 0.5g.L for growth experiments and 1g.L" for 
biotransformation experiments. Cholesterol (1g.L, Sigma) 
was added as Solid to mineral liquid medium, finely dispersed 
by Sonication and Subsequently autoclaved. Growth on min 
eral liquid media was followed spectrophotometrically (AD, 
9OHAD, HIP, HIL) or by determination of total protein con 
tent of the culture (cholesterol, BioRad protein assay). 
Sucrose (Suc) sensitivity of Rhodococcus strains was tested 
on LBP agar supplemented with 10% (w/v) sucrose (LBPS). 
E. coli strains (Table 1) were grown in Luria-Bertani (LB) 
broth at 37° C. BBL agar (1.5% (wt/vol)) was added for 
growth on Solid medium. 
(L) General Cloning Techniques 
0028 DNA modifying enzymes were purchased from 
Boehringer (Mannheim, Germany). New England Biolabs 
(Beverly, Mass.) or Amersham Pharmacia Biotech AB (Upp 
sala, Sweden) and were used as described by the manufac 
turer. Isolation of DNA restriction fragments from agarose 
gels was done using the GeneClean II (Q-BIOgene, Carlsbad, 
Calif., USA) gel extraction kit according to protocol. All 
DNA manipulations were done according to standard proto 
cols. PCR was performed under Standard conditions using 
Expand polymerase (Boehringer) unless stated otherwise: 30 
cycles of 1 min 95°C. 45 sec 60°C., 1.5 min 72° C. Genomic 
DNA isolation and colony PCR was performed as described 
(van der Geize et al.: Appl. Environ. Microbiol. 66: 2029 
2036 (2000)) Transformation of Rhodococcus strains for 
unmarked gene deletion experiments was performed by 
mobilization of the mutagenic vector from E. coli S17-1 
(Table 1) to the Rhodococcus strain by conjugation as 
described (van der Geize et al.: FEMS Microbiol. Lett. 205: 
197-202 (2001)). 
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(M) UV Mutagenesis of R. erythropolis Strain SQ1 
UV-induced mutagenesis essentially was done as previously 
described (van der Geize et al.: FEMS Microbiol. Lett. 205: 
197-202 (2001)). HIL growth negative mutants, growing well 
on glucose mineral agar plates, but blocked in growth on 
mineral agar plates supplemented with 0.5g.L.' HIL, were 
selected for further work. 
(N) Functional Complementation of Rhodococcus mutants 
AP10 and AP20 
Electro-competent cells of mutant strains AP10 and AP20 
were transformed with R. erythropolis genomic library (van 
der Geize et al., Mol Microbiol 45:1007-1018, (2002)). 
Transformations were replica plated onto HIL mineral agar 
plates (without antibiotic) for Screening. Functional comple 
mentation of HIL growth negative mutants was observed after 
approximately 5 days. Plasmid DNA was isolated from the 
respective Rhodococcus tranformants and used for re-tranfor 
mation of the Rhodococcus mutants to check for genuine 
funstional complemetation by the isolated plasmid. 
Bioconversion Experiments and Analysis by GC, HPLC and 
TLC 
0029. R. erythropolis parent strain SQ1 and mutants were 
grown in 50 mL glucose (20 mM) mineral medium for 2-3 
days (ODoo->2). Steroids, HIP or HIL were added (1 g L' 
final concentration) and bioconversion was followed during 5 
days (in duplicate). Samples for GC and TLC analysis (0.5 
mL) were acidified with 10ul 10% HSO. Sample extraction 
was done using ethylacetate (2 mL). GC analysis was per 
formed on a GC8000 TOP (Thermoquest Italia, Milan, Italy) 
with AT-5 MS column measuring 30 m by 0.25 mm (inner 
diameter) and a 0.25 um film (Alltech, Ill., USA.) and FID 
detection at 300° C. Chromatographs obtained were analysed 
using Chromduest V 2.53 software (Thermoguest). For high 
performance liquid chromatography (HPLC) analysis, 
samples were diluted five times with methanol-water (70:30) 
and filtered (0.45 um). HPLC analysis was performed on a 
reversed-phase Lichrosorb 10RP18 (5u) column, measuring 
250 by 4.6 mm (Varian Chrompack International, Middel 
burg, the Netherlands) with UV detection at 254 nm, and a 
liquid phase of methanol-water (60:40) at 30° C. TLC was 
done with Kieselgel 60 Fs 10x20 cm (Merck, Darmstadt, 
Germany) developed in toluene/ethylacetate 1:1. 
(P) Construction of Mutagenic Plasmids pAR31 and 
pAR2015 for ipdAB and ipdF Unmarked Gene Deletion 
For unmarked in-frame deletion of ipdA and ipdB, plasmid 
pAR31 (Table 1) was constructed. A 790 bp PCR fragment 
(PCR product 1), containing part of ipdE and the beginning of 
ipdA, was obtained using R. erythropolis SQ1 genomic DNA 
with P1 (Xbal) forward primer 
(5' GCGTCTAGACTGCGAGCCGAGGGACGCG 3'(SEQ 
ID NO:8)) and P2 (BamHI) reverse primer (5 GCGGGATC 
CGTCCGAACGCAGAATCGCACG 3' (SEQ ID NO: 9)) 
(FIG. 2). A second PCR fragment (800 bp, PCR product 2), 
containing the end of ipdB and part of ipdD, was amplified 
from R. erythropolis SQ1 genomic DNA with P3 (BamHI) 
forward primer (5 GCGGGATCCCTCGCCGAGGCCGG 
TATCAC3' (SEQID NO: 10)) and P4 (Smal) reverse primer 
(5 GCGCCCGGGCTTGCGCGAGACCGTCGTATC 3' 
(SEQID NO: 11)). Underlined restriction sites, also indicated 
between brackets for each primer, were included in the four 
primers to ensure in-frame linkage of the ipdA start codon and 
the ipdB stop codon. PCR product 2 was cloned into Smal 
digested pK18mobsacB (Table 1), resulting in plasmid 
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pAR30. Subsequently, PCR product 1 was digested with Xbal 
and BamHI and cloned into Xbal/BamHI digested pAR30, 
resulting in plasmidp AR31. For ipdF gene deletion, a 2.54 kb 
Xhol fragment of pAR2002 was cloned into pBlueScript 
II(KS), rendering pAR2013. The internal part (430 bp) of the 
ipdF gene was deleted by BclI/NcoI digestion of pAR2013 
and blunt-ended self-ligation after Klenow treatment. The 
resulting plasmid (pAR2014) was digested with Xhol and a 
Strain or plasmid 
R. erythropolis SQ1 
Characteristics 
Parent strain, HIL 
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2.11 kb DNA fragment. containing the ipdF deletion, was 
cloned into SalI digested pK18mobsacB, yielding plasmid 
pAR2015 used for ipdF gene deletion. Genuine ipdF gene 
deletion was checked by PCR with genomic DNA isolated 
from strain RG33 with IpdF-F forward primer (5'-ATA 
CATATGAGTGGATTGGTCGACGGAC (SEQ ID NO : 
12)) and IpdF-R reverse primer (5'-ATAGGATC 
CCTACGCTCCGTACACCGGCGTC (SEQ ID NO: 13)). 
TABLE 1 
Strains and plasmids used in this study. 
Reference? origin 
Quan S. et al., Plasmid 29: 74-79 
(1993) 
R. erythropolis RG33 ipdF mutant of strain SQ1, HIL This study 
R. erythropolis RG37 IpdAB mutant of strain SQ1, HIL This study 
R. erythropolis AP10 UV-mutant of strain SQ1, HIL This study 
R. erythropolis AP20 UV-mutant of strain SQ1, HIL This study 
E. Coi DHSC. Host for general cloning steps Bethesda Res. Lab. 
E. Coi S17-1 Strain for conjugal mobilization of Simon et al.: Biotechnology 1:784-791 
pK18mobsacB derivatives to Rhodococcus (1983) 
strains 
pBlueScript(II) KS bla lacz Stratagene 
pK18mobsacB aphII sacB oriT (RP4) lacz Schäfer et al.: Gene 145: 69-73 (1994) 
pRESQ Rhodococcus-E. coli shuttle vector van der Geize R. et al.: Mol. Microbiol. 
45: 1007-1018 (2002) 
AR1 pRESQ containing 5.2 kb genomic fragment This study 
of R. erythropolis carrying ipdA and ipdB 
AR1O pRESQ carrying ipdA and ipdB on a 2.88 kb This study 
NcoIHindIII fragment of pAR1 (HindIII 
ocated on cloning vector) 
AR30 PCR product 2, obtained with primers P3 This study 
and P4 (FIG. 2), cloned in SmaI digested 
bK18mobSacB 
AR31 PCR product 1, obtained with primers P1 This study 
and P2 (FIG. 2) cloned into Xbal/BamHI 
digested paR30; used for ipdAB gene 
deletion in SQ1, yielding RG37 
AR2OOO pRESQ containing 6.1 kb genomic fragment This study 
of R. erythropolis carrying ipdF 
AR2002 Self-ligation of 9.55 kb fragment of pAR2000 This study 
ollowing Asp718I digestion 
AR2003 Asp718I fragment (3.2 kb) of pAR2000 This study 
igated into Asp718I digested pRESQ 
AR2010 Self-ligation of Asp700I Asp718I digested This study 
pAR2002 (blunt-ended with Klenow) 
PAR2013 2.54 kb XhoI fragment of pAR2002 cloned in This study 
XhoI site pBlueScript(II)KS 
AR2014 Self-ligation of BclINcoI digested paR2013 This study 
(5 kb, blunt-ended with Klenow) 
AR2O15 2.1 kb XhoI fragment of paR2014 cloned in This study 
SalI site of pK18mobsac8; used for ipdF 
gene deletion in SQ1, yielding RG33 
SEQUENCE LISTING 
<16 Oc NUMBER OF SEO ID NOS : 13 
<210 SEQ ID NO 1 
<211 LENGTH: 43 OO 
&212> TYPE: DNA 
<213> ORGANISM: Rhodococcus erythropolis 
<4 OO SEQUENCE: 1 
gggc.cggagg cc ctacgct C cqtacaccgg C9tcggaatc. tcc.gc.cttct coaa.ca.gcgt. 60 
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<210 SEQ ID NO 3 
<211 LENGTH: 3O2 
&212> TYPE: PRT 
<213> ORGANISM: Rhodococcus erythropolis 
<4 OO SEQUENCE: 3 
Met Ala Ser Lys Arg Asp Llys Thir Lys Ser Lieu. Asp Glu Val Val Gly 
1. 5 1O 15 
Glu Lieu. Arg Ser Gly Met Thir Ile Gly Lieu. Gly Gly Trp Gly Ser Arg 
2O 25 3 O 
Arg Llys Pro Met Ala Phe Val Arg Ala Ile Lieu. Arg Ser Asp Ile Llys 
35 4 O 45 
Asp Lieu. Thr Val Val Thr Tyr Gly Gly Pro Asp Lieu. Gly Lieu. Lieu. Cys 
SO 55 6 O 
Ser Ala Gly Llys Wall Lys Lys Ala Tyr Tyr Gly Phe Val Ser Lieu. Asp 
65 70 7s 8O 
Ser Ala Pro Phe Tyr Asp Pro Trp Phe Ala Lys Ala Arg Thir Ala Gly 
85 9 O 95 
Glu Ile Glu Val Arg Glu Met Asp Glu Gly Met Val Lys Cys Gly Lieu. 
OO OS 1O 
Glu Ala Ala Ala Ala Arg Lieu Pro Phe Lieu Pro Ile Arg Ala Gly Lieu. 
15 2O 25 
Gly Ser Asp Val Arg Asn. Phe Trp Gly Asp Glu Lieu Lys Thr Val Thr 
3O 35 4 O 
Ser Pro Tyr Pro Glu Ala Asp Gly Arg Ser Glu Thir Lieu. Ile Ala Met 
45 SO 55 160 
Pro Ala Lieu. Asn Lieu. Asp Ala Ser Phe Wal His Lieu. Asn Lieu. Gly Asp 
65 70 7s 
Llys His Gly Asn Ala Ala Tyr Asn Gly Val Asp Pro Tyr Phe Asp Asp 
8O 85 90 
Lieu. Tyr Cys Met Ala Ala Glu Lys Arg Tyr Val Ser Val Glu Arg Ile 
95 2 OO 2O5 
Val Glu Thr Glu Glu Lieu Val Lys Ser Val Pro Lieu. Glin Asn Lieu. Lieu 
210 215 22O 
Lieu. Asn Arg Met Met Val Asp Ala Val Val Glu Ala Pro Asn Gly Ala 
225 23 O 235 24 O 
His Phe Thir Lieu Ala Gly Glu Ser Tyr Gly Arg Asp Glu Lys Phe Glin 
245 250 255 
Arg His Tyr Ala Glu Ala Ala Lys Thr Pro Glu Ser Trp Gln Thr Phe 
26 O 265 27 O 
Val Asp Thir Phe Lieu. Ser Gly Ser Glu Glu Asp Tyr Glin Ala Ala Val 
27s 28O 285 
Llys Llys Phe Ala Asp Ser Ser Lys Ala Gly Glu Glin Ala Lys 
290 295 3 OO 
<210 SEQ ID NO 4 
<211 LENGTH: 756 
&212> TYPE: DNA 
<213> ORGANISM: Rhodococcus erythropolis 
&220s FEATURE: 
<221 NAME/KEY: CDS 
<222> LOCATION: (1) . . (753) 
<223> OTHER INFORMATION: ipdB 
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Ala Glu Ile Phe Ser Gly Ala Gly Glu Ile Met Ala Ser Pro Met Ser 
2O 25 3 O 
Thir Ser Ser Thr Ile Gly Ala Arg Lieu Ala Arg Lieu. Thir Thr Glu Pro 
35 4 O 45 
Asp Lieu. Lieu. Ile Thr Asp Gly Glu Ala Lieu. Ile Lieu. Glu Asp Thr Pro 
SO 55 6 O 
Ala Val Gly. Thir Lys Gly Pro Ile Glu Gly Trp Met Pro Phe Arg Lys 
65 70 7s 8O 
Val Phe Asp Val Val Ala Ser Gly Arg Arg His Val Val Met Gly Ala 
85 9 O 95 
Asn Glin Lieu. Asp Arg His Gly Asn Glin Asn Lieu. Ser Ala Phe Gly Pro 
OO OS 1O 
Lieu. Glin Gln Pro Thr Arg Gln Met Phe Gly Val Arg Gly Ala Pro Gly 
15 2O 25 
Asn Thr Ile Asn His Ala Thir Ser Tyr Phe Val Pro Llys His Ser Lys 
3O 35 4 O 
Arg Val Phe Val Asp Llys Val Asp Val Val Cys Gly Val Gly Tyr Asp 
45 SO 55 160 
Glin Ile Asp Pro Glu Asn Pro Ala Tyr Lys Tyr Lieu. Asn. Ile Pro Arg 
65 70 7s 
Val Val Thr Asn Lieu. Gly Val Phe Asp Phe Gly Gly Pro Gly Asn Thr 
8O 85 90 
Phe Arg Ala Lieu. Ser Lieu. His Pro Gly Val Thr Ala Glu Glu Val Ala 
95 2 OO 2O5 
Glu Asn. Thir Ser Phe Glu Val Ala Gly Lieu Ala Glu Ala Gly Ile Thr 
210 215 22O 
Arg Asp Pro Thr Ala Glu Glu Lieu. His Lieu. Ile Arg Glu Thir Lieu. Asp 
225 23 O 235 24 O 
Pro Arg Asn Lieu. Arg Asp Arg Glu Val Ser Ala 
245 250 
<210 SEQ ID NO 6 
<211 LENGTH: 91.5 
&212> TYPE: DNA 
<213> ORGANISM: Rhodococcus erythropolis 
&220s FEATURE: 
<221 NAME/KEY: CDS 
<222> LOCATION: (1) ... (912) 
<223> OTHER INFORMATION: ipdF 
<4 OO SEQUENCE: 6 
atg agt gga ttg gtc. gac gga cc gta gtC atc atc acc ggg gct ggit 48 
Met Ser Gly Lieu Val Asp Gly Arg Val Val Ile Ile Thr Gly Ala Gly 
1. 5 1O 15 
cgc ggg at C gga cit gcg cat gcc ttg gcd titt gct gcc gag ggc gcc 96 
Arg Gly Ile Gly Arg Ala His Ala Lieu Ala Phe Ala Ala Glu Gly Ala 
2O 25 3 O 
aag gt C gtC gtC aac gac atc ggit gcg ggit gcc gac ggt to C gag acc 144 
Llys Val Val Val Asn Asp Ile Gly Ala Gly Ala Asp Gly Ser Glu Thir 
35 4 O 45 
ggt gag agt ccg gcc gag cag gtt gtC gog gag atc atc gcc gcc ggit 192 
Gly Glu Ser Pro Ala Glu Glin Val Val Ala Glu Ile Ile Ala Ala Gly 
SO 55 6 O 
ggc caa gCa gtg gtc. aac gga gac gac git C gcc gac tig gC9 ggc gcc 24 O 
Gly Glin Ala Val Val Asn Gly Asp Asp Wall Ala Asp Trp Ala Gly Ala 
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Gly Glu Ser Pro Ala Glu Glin Val Val Ala Glu Ile Ile Ala Ala Gly 
SO 55 6 O 
Gly Glin Ala Val Val Asn Gly Asp Asp Wall Ala Asp Trp Ala Gly Ala 
65 70 7s 8O 
Glu Asn Lieu. Ile Llys Thr Ala Ile Asp Thir Phe Gly Gly Lieu. Asp Wall 
85 9 O 95 
Lieu Val Asn. Asn Ala Gly Phe Lieu. Arg Asp Arg Met Lieu Val Gly Met 
OO OS 1O 
Ser Glu Gly Glu Trp Asp Ala Val Ile Arg Val His Lieu Lys Gly His 
5 2O 25 
Phe Ala Pro Lieu. Arg His Ala Ala Ala Tyr Trp Arg Ala Glu Ala Lys 
3O 35 4 O 
Ala Gly Lys Thr Val Asp Ala Arg Ile Ile Asn. Thir Ser Ser Gly Ala 
45 SO 55 160 
Gly Lieu. Glin Gly Ser Ile Gly Glin Gly Asn Tyr Ala Ala Ala Lys Ala 
65 70 7s 
Gly Ile Ala Glu Met Thir Ile Glin Ala Ala Ala Glu Lieu Lys Asn Tyr 
8O 85 90 
Gly Val Ser Val Asn Ala Ile Ala Pro Ala Ala Arg Thr Arg Met Thr 
95 2 OO 2O5 
Val Gly Ala Gly Gly Ala Met Ala Glu Ser Met Ala Ala Pro Glu Glu 
210 215 22O 
Gly Phe Asp Ala Met Ala Pro Glu Asn Ile Ser Pro Leu Val Val Trp 
225 23 O 235 24 O 
Lieu. Gly Ser Ala Glu Ser Lys Asp Val Thr Gly Arg Val Phe Glu Val 
245 250 255 
Glu Gly Gly Lys Ile Thr Val Ala Glu Gly Trp Arg His Gly Pro Ser 
26 O 265 27 O 
Glu Asp Llys Gly Asp Arg Trp Asp Pro Lys Glu Ile Gly Pro Val Val 
27s 28O 285 
Ala Thr Lieu. Lieu. Glu Lys Ala Glu Ile Pro Thr Pro Val Tyr Gly Ala 
290 295 3 OO 
<210 SEQ ID NO 8 
<211 LENGTH: 28 
&212> TYPE: DNA 
<213> ORGANISM: Artificial 
&220s FEATURE: 
<223> OTHER INFORMATION: P1 (Xbal) Forward primer 
<4 OO SEQUENCE: 8 
gcgt.ct agac to gagcc.ga gggacgcg 28 
<210 SEQ ID NO 9 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial 
&220s FEATURE: 
<223> OTHER INFORMATION: P2 (BamHI) reverse primer 
<4 OO SEQUENCE: 9 
gcgggat.ccg tcc.gaacgca gaatcgcacg 3 O 
<210 SEQ ID NO 10 
<211 LENGTH: 29 
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&212> TYPE: DNA 
<213> ORGANISM: Artificial 
&220s FEATURE: 
<223> OTHER INFORMATION: P3 (BamHI) forward primer 
<4 OO SEQUENCE: 10 
gcgggat.ccc ticgc.cgaggc cqgitat cac 
<210 SEQ ID NO 11 
<211 LENGTH: 29 
&212> TYPE: DNA 
<213> ORGANISM: Artificial 
&220s FEATURE: 
<223> OTHER INFORMATION: P4 (SmaI) reverse primer 
<4 OO SEQUENCE: 11 
gcgggat.ccc ticgc.cgaggc cqgitat cac 
<210 SEQ ID NO 12 
<211 LENGTH: 28 
&212> TYPE: DNA 
<213> ORGANISM: Artificial 
&220s FEATURE: 
<223> OTHER INFORMATION: IpdF-F forward primer 
<4 OO SEQUENCE: 12 
atacatatga gtggattggt cacggac 
<210 SEQ ID NO 13 
<211 LENGTH: 31 
&212> TYPE: DNA 
<213> ORGANISM: Artificial 
&220s FEATURE: 
<223> OTHER INFORMATION: IpdF-R reverse primer 
<4 OO SEQUENCE: 13 
ataggat.ccc tacgct cogt acaccggcgt C 
1. A method to construct a genetically modified Strain of a 
steroid-degrading micro-organism, wherein the method com 
prises inactivation of at least one gene involved in methyl 
hexahydroindanedione propionate degradation. 
2. The method according to claim 1, wherein the method 
comprises inactivation of multiple genes involved in methyl 
hexahydroindanedione propionate degradation. 
3. The method according to claim 1, wherein at least one 
gene encoding a HIP CoA transferase is inactivated. 
4. The method according to claim 3, wherein the HIP CoA 
transferase genes ipdA and ipdB are inactivated. 
5. The method according to claim 1 wherein a gene encod 
ing a HIL-(3'C-hydroxypropionyl)-CoA dehydrogenase 
(ipdF) is inactivated. 
6. The method according to claim 1, wherein any gene is 
inactivated by UV-irradiation. 
7. The method according to claim 1, wherein any gene is 
deleted by unmarked gene deletion. 
8. The method according to claim 1, wherein the micro 
organism belongs to the family of Actinomycetesis. 
9. The method according to claim 8, wherein the micro 
organism belongs to the genus Rhodococcus. 
10. The method according to claim 9, wherein the micro 





11. A genetically modified Strain of a micro-organism pre 
pared according to claim 1. 
12. The genetically modified strain a-cording to claim 11 
being Rhodococcus erythropolis RG37. 
13. The genetically modified strain according to claim 11, 
being Rhodococcus erythropolis RG33. 
14. A method for preparing a steroid intermediate, the 
method comprising 
(a) preparing a genetically modified strain of a steroid 
degrading micro-organism, which comprises inactiva 
tion of at least one gene involved in methylhexahydroin 
danedione propionate degradation; and 
b) adding a steroid starting material to the genetically 
modified Strain of step (a). 
15. The method according to claim 14, wherein the steroid 
intermediate is 3ao-H-4C.(3'-propionic acid)-7a3-methyl 
hexahydro-1,5-indanedione (HIP) and/or 3-hydroxy-9.10 
secoandrosta-1,3,5(10)-triene-9,17-dione (3-HSA) and the 
steroid starting material is 9C.-hydroxy-4-androstene-3,17 
dione (90HAD). 
16. The method according to claim 14, wherein the steroid 
intermediate is 1,4-androstadiene-3,17-dione (ADD) and the 
steroid starting material is 4-androstene-3,17-dione (AD). 
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17. The method according to claim 14, wherein the steroid 
intermediate is 3ao-H-4C.(3'-propionic acid)-5C.-hydroxy 
7af3-methylhexahydro-1-indanone-6-lactone (HIL) and the 
steroid starting material is 4-androstene-3,17-dione (AD). 
18. An IpdA protein comprising the amino acid sequence 
SEQ ID NO:3 or orthologues therefrom. 
19. An IpdB protein comprising the amino acid sequence 
SEQ ID NO:5 or orthologues therefrom. 
20. An IpdF protein comprising the amino acid sequence 
SEQ ID NO:7 or orhologues therefrom. 
21. The DNA sequence encoding an IpdA protein accord 
ing to claim 18. 
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22. The DNA sequence encoding an IpdB protein accord 
ing to claim 19. 
23. The DNA sequence encoding an IpdF protein accord 
ing to claim 20. 
24. A DNA sequence comprising nucleotides 1814-2722 of 
SEQID NO:1. 
25. A DNA sequence comprising nucleotides 2719-3474 of 
SEQID NO:1. 
26. A DNA sequence comprising nucleotides 927-13 of 
SEQID NO:1. 
